Maxigen Biotech Inc.

TWSE:1783 Stock Report

Market Cap: NT$3.8b

Maxigen Biotech Balance Sheet Health

Financial Health criteria checks 6/6

Maxigen Biotech has a total shareholder equity of NT$1.4B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.5B and NT$131.9M respectively. Maxigen Biotech's EBIT is NT$149.9M making its interest coverage ratio -6. It has cash and short-term investments of NT$431.1M.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ratio-6x
CashNT$431.08m
EquityNT$1.36b
Total liabilitiesNT$131.88m
Total assetsNT$1.49b

Recent financial health updates

No updates

Recent updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Financial Position Analysis

Short Term Liabilities: 1783's short term assets (NT$619.6M) exceed its short term liabilities (NT$131.4M).

Long Term Liabilities: 1783's short term assets (NT$619.6M) exceed its long term liabilities (NT$510.0K).

Debt to Equity History and Analysis

Debt Level: 1783 is debt free.

Reducing Debt: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 25.3%.

Debt Coverage: 1783 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1783 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.